1. Home
  2. PBT vs OMER Comparison

PBT vs OMER Comparison

Compare PBT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permian Basin Royalty Trust

PBT

Permian Basin Royalty Trust

HOLD

Current Price

$35.32

Market Cap

1.0B

Sector

Energy

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$17.80

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBT
OMER
Founded
1980
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
844.6M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
PBT
OMER
Price
$35.32
$17.80
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
88.1K
1.5M
Earning Date
03-13-2026
05-14-2026
Dividend Yield
1.50%
N/A
EPS Growth
N/A
98.15
EPS
N/A
0.77
Revenue
N/A
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$233.22
P/E Ratio
$57.37
$23.96
Revenue Growth
N/A
N/A
52 Week Low
$16.25
$4.06
52 Week High
$37.00
$19.65

Technical Indicators

Market Signals
Indicator
PBT
OMER
Relative Strength Index (RSI) 64.00 54.24
Support Level $32.75 $10.82
Resistance Level N/A $19.60
Average True Range (ATR) 0.86 0.79
MACD -0.10 -0.38
Stochastic Oscillator 62.75 45.57

Price Performance

Historical Comparison
PBT
OMER

About PBT Permian Basin Royalty Trust

Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: